The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
13
Administered orally.
Beijing Cancer hospital
Beijing, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Shanghai East Hospital
Shanghai, China
Blood Institute of the Chinese Academy of Medical science
Tianjin, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events
Time frame: Day 1 through 28 days after last dose or start of new anticancer therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.